Previous 10 | Next 10 |
2023-05-04 11:04:08 ET Organon & Co. (OGN) Q1 2023 Earnings Conference Call May 04, 2023 08:30 A.M. ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Matthew Walsh - CFO Conference Call Participants Unidentified Analyst - Evercore ...
2023-05-04 07:31:34 ET Organon press release ( NYSE: OGN ): Q1 Non-GAAP EPS of $1.08 misses by $0.08 . Revenue of $1.54B (-1.9% Y/Y) in-line. Full year 2023 financial guidance ranges affirmed For further details see: Organon Non-GAAP EPS of $1.08 misses b...
First quarter 2023 revenue of $1,538 million First quarter 2023 diluted earnings per share of $0.69 and non-GAAP Adjusted diluted earnings per share of $1.08 Both reported and non-GAAP Adjusted diluted earnings per share include a negative impact of $0.03 per share for acquired in-process...
2023-05-03 14:25:08 ET Organon ( NYSE: OGN ) is scheduled to announce Q1 earnings results on Thursday, May 4th, before market open. The consensus EPS estimate is $1.16 and the consensus revenue estimate is $1.54B. Over the last 1 year, OGN has beaten EPS estimates ...
Organon (NYSE: OGN), a global women’s healthcare company will release its first quarter 2023 financial results on May 4, 2023, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT. Interested parties may access the live call via webcast on the Organon w...
Lifezone Metals launches off-take marketing process for nickel, copper and cobalt from the Kabanga nickel project PR Newswire LONDON , April 19, 2023 /PRNewswire/ -- Lifezone Holdings Limited ("Lifezone Metals") has previously announced entry into a Business Comb...
2023-03-24 14:03:55 ET Summary Organon & Co. has seen mostly margin disappointments since the spinoff from Merck & Co., Inc. While the performance is not comforting, valuations are non-demanding. Leverage is high, but stabilization in the business, longer-term maturiti...
2023-03-16 08:34:23 ET Raymond James launched its coverage on Organon ( NYSE: OGN ) with an Outperform recommendation citing its potential in the biosimilar space with the upcoming launch of Hadlima, a copycat version of AbbVie's ( ABBV ) blockbuster arthritis therapy Humira...
2023-03-12 10:00:00 ET Biosimilar medication, generic versions of typically expensive biologic-based drugs, are set to save patients and the health care system $180B over the next five years as even more hit the market. New launches and an expected increase in uptake of biosimilars ...
Building on Organon’s Prior FP2030 Commitment, the Company Announces $30 Million in New Funding to Fuel Global Action and Community-Driven Solutions Needed by the 121 Million Women and Girls Who Experience Unplanned Pregnancies Each Year Organon (NYSE: OGN), a global healthcare c...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, BC / ACCESSWIRE / July 31, 2024 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce a new significant gold-silver discovery, called the Navidad vein system, on the Ermitaño Mine concessions in Sonora, Mexico where the Company holds a...
VANCOUVER, BC / ACCESSWIRE / July 24, 2024 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce updates for its partner funded exploration stage projects and royalties. Highlights Estimated 30,000 metres of drilling in seven planned or comp...
Company estimates $15 million of milestone expense in the second quarter Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its second quarter 2024 financial results on August 6, 2024, prior to the company’s webcast and conference...